APG Asset Management N.V. Acquires 12,600 Shares of Abbott Laboratories $ABT

APG Asset Management N.V. lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 1.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,000,800 shares of the healthcare product maker’s stock after purchasing an additional 12,600 shares during the period. APG Asset Management N.V. owned 0.06% of Abbott Laboratories worth $134,047,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares during the period. Sivia Capital Partners LLC raised its position in shares of Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after purchasing an additional 162 shares during the period. United Bank lifted its holdings in shares of Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after purchasing an additional 2,001 shares in the last quarter. Assetmark Inc. increased its position in shares of Abbott Laboratories by 14.5% during the second quarter. Assetmark Inc. now owns 181,491 shares of the healthcare product maker’s stock worth $24,685,000 after acquiring an additional 23,050 shares in the last quarter. Finally, GAM Holding AG raised its holdings in shares of Abbott Laboratories by 2.9% in the 2nd quarter. GAM Holding AG now owns 10,490 shares of the healthcare product maker’s stock worth $1,427,000 after acquiring an additional 297 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the stock in a transaction dated Wednesday, February 4th. The shares were bought at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the transaction, the director directly owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.46% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on ABT. Piper Sandler decreased their price objective on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a report on Friday, January 23rd. Citigroup decreased their price target on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Freedom Capital raised shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Raymond James Financial lowered their target price on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, Argus cut their price target on shares of Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Trading Down 0.1%

Shares of ABT stock opened at $116.17 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The firm has a market cap of $201.87 billion, a P/E ratio of 31.23, a PEG ratio of 1.85 and a beta of 0.75. The company has a 50 day moving average of $117.34 and a 200-day moving average of $125.26. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. The business had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.Abbott Laboratories’s revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.